An independent data monitoring committee concluded Bayer’s experimental drug for atrial fibrillation would not be more effective than Eliquis, a blockbuster product currently used for the indication. Consequently, Bayer decided to stop that Phase 3 test for the once-daily oral small molecule.
RapidAI recently closed a $75 million Series C funding round led by Vista Credit Partners. The company offers an AI platform that helps hospital care teams triage and treat stroke patients more quickly.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Alviss.ai CEO and Founder Dr. Pavel Overtchouk talks about how the company’s stroke prediction software seeks to be the first attempt to apply predictive medicine to cardiovascular interventions and heart surgery.
Wallaby, which has its main offices in Laguna Hills, California and Shanghai, China, and Bochum, Germany-based phenox have been strategic partners since 2019. The deal is valued at about 500 million euros, including milestone payments, or the equivalent of more than $542 million.
The mortality rates at rural hospitals for certain conditions, including heart attacks and stroke, decreased in the years following a merger or an acquisition compared with facilities that remained independent, a new study shows. This is a departure from research done on the effects of M&A on urban hospitals.
Imperative Care, a company with two FDA-cleared devices for stroke treatment, recently raised $160 million in a funding round led by D1 Capital Partners. It’s using the funds to build a portfolio of companies to treat stroke and vascular disease.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Biogen paid $18 million to acquire a drug that TMS Co. of Japan tested in patients with acute ischemic stroke. The acquisition follows the report of preliminary mid-stage data showing the drug led to no cases of a potentially fatal complication associated with currently available stroke therapies.
MedRhythms, a digital health startup using sensors and music for post-stroke walking rehabilitation, received an FDA Breakthrough Device Designation.
The company, Portland, Maine-based MedRhythms, is using sensors, software and music to build evidence-based neurologic interventions to help stroke patients improve their walking.
According to findings presented at the American College of Cardiology's annual meeting, 0.5 percent of the more than 400,000 study participants received a notification about irregular pulse and 84 percent of participants who received irregular pulse notifications were found to be in atrial fibrillation at the time of the notification.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
With the additional $1.72 million in grants for further development of its stroke rehab technology, the Irvine, California-based company's funding now totals more than $8 million.
The study out of Vanderbilt University Medical Center found 14 percent of individuals with genetic variants impacting the kidney had kidney transplants and 10 percent with another variant had liver transplants. These transplants could have been avoided had the underlying genetic cause been disclosed.
Viz.AI's product uses a form of artificial intelligence to analyze computed tomography images of the brain to detect signs of a stroke.
Tucson, Arizona-based NuvOx Pharma has major plans for treating life-threatening hypoxia with a drug originally approved as a contrasting agent in Europe.
AiCure's tool uses a form of artificial intelligence for facial recognition to confirm that patients have taken the correct medication.